By Fineline Cube 
Amgen (NASDAQ: AMGN) reported fourth‑quarter 2025 revenue of USD 9.9 billion, up 9% year‑over‑year (YOY), bringing full‑year revenue to USD 36.8 billion, a 10% YOY increase. Full‑year product sales totaled USD 35.148 billion, growing 10% driven by a 13% volume increase, partially offset by a 3% net selling price decline.
Financial Performance Summary
| Metric | Q4 2025 | Full‑Year 2025 | YOY Growth |
|---|---|---|---|
| Total Revenue | USD 9.9 B | USD 36.8 B | +10% |
| Product Sales | — | USD 35.148 B | +10% |
| Volume Growth | — | — | +13% |
| Price Impact | — | — | -3% |
| 2026 Guidance | — | USD 37.0–38.4 B | — |
Key Product Performance
| Product | 2025 Sales | YOY Growth | Strategic Role |
|---|---|---|---|
| Prolia (denosumab) | USD 4.414 B | +1% | Top seller, osteoporosis leader |
| Repatha (evolocumab) | USD 3.016 B | +36% | PCSK9 growth driver |
| Otezla (apremilast) | USD 2.265 B | +7% | Inflammatory disease staple |
| Evenity (romosozumab) | USD 2.100 B | +34% | Osteoporosis expansion |
| Blincyto (blinatumomab) | USD 1.559 B | +28% | Oncology biologic |
| Tezspire (tezepelumab) | USD 1.478 B | +52% | Asthma biologic growth |
Portfolio Highlights:
- 14 products exceeded USD 1 billion in sales
- 13 products achieved double‑digit annual sales growth
Strategic Outlook & Market Context
- 2026 Guidance: Revenue projected at USD 37.0–38.4 billion, reflecting continued volume growth and portfolio expansion
- Growth Drivers: Biologics and biosimilars momentum, offset by pricing pressures in mature markets
- Investment Focus: R&D reinvestment in oncology, cardiovascular, and inflammation pipeline
Forward‑Looking Statements
This brief contains forward‑looking statements regarding revenue projections, product performance, and market growth for 2026. Actual results may differ due to competitive dynamics, pricing pressures, and regulatory changes.-Fineline Info & Tech